The cumulative cancer incidences of MLH1, MSH2, MSH6, or PMS2 variant carriers up to age 75 are as follows: MLH1: 81% (females), 71.4% (males); MSH2: 84.3% (females), 75.2% (males); MSH6: 61.8% (females), 41.7% (males); and PMS2: 34.1% (both sexes). The gene discussed is MSH2; the disease is cancer.